Novartis' net income 2007-2023

Novartis AG, one of the world’s top pharmaceutical companies, reported a high net income of nearly 15 billion U.S. dollars in 2023. However, two years before, the net income was even higher, at a record high 24 billion dollars.

Novartis revenue and expenses

Being a Swiss-based company, Novartis generated around one third of its revenue, namely about 15 billion U.S. dollars, in Europe in 2023. With approximately 18 billion U.S. dollars, the United States was the company's most important market in that year. Novartis AG made 31.8 billion U.S. dollars from its branded pharmaceuticals ("Promoted brands") segment that year, the company’s largest segment. Novartis spun-off its generic drugs division Sandoz in mid-2023, while eye care division Alcon was spun off in back April 2019. The company spends most of its resources on SG&A (selling, general and administration): expenses for this category reached around 12.5 billion U.S. dollars in 2023. Research and development expenditures amounted to some 11.4 billion U.S. dollars in the same year.